<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04144049</url>
  </required_header>
  <id_info>
    <org_study_id>MT11-KR18SMF203</org_study_id>
    <nct_id>NCT04144049</nct_id>
  </id_info>
  <brief_title>A Phase II Study to Evaluate the Efficacy and Safety of MT921 in Subjects With Moderate to Severe Submental Fat</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Dose Ranging, Parallel, Multi-center, Phase II Study to Evaluate the Efficacy and Safety of MT921 in Subjects With Moderate to Severe Submental Fat</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medy-Tox</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medy-Tox</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a randomized, double-blind, placebo-controlled, dose-ranging, parallel,
      multi-center, phase II study to evaluate the efficacy and safety of MT921 in subjects with
      moderate to severe submental fat.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 10, 2019</start_date>
  <completion_date type="Anticipated">September 10, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 10, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Responder rate of 2-grade improvement in CA-SMFRS</measure>
    <time_frame>4 weeks after the last treatment session</time_frame>
    <description>Proportion of subjects who have at least a 2-grade improvement from basleine on the Clinician Assessed-SubMental Fat Rating Scale (5-point scale, 0-No submental fat to 4-Excessive submental fat) at 4 weeks after the last treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Responder rate of 2-grade improvement in PA-SMFRS</measure>
    <time_frame>4 weeks after the last treatment session</time_frame>
    <description>Proportion of subjects who have at least a 2-grade improvement from basleine on the Patient Assessed-SubMental Fat Rating Scale (5-point scale, 0-No submental fat to 4-Excessive submental fat) at 4 weeks after the last treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Responder rate of 1-grade improvement in CA-SMFRS</measure>
    <time_frame>4 weeks after the last treatment session</time_frame>
    <description>Proportion of subjects who have at least a 1-grade improvement from basleine on the Clinician Assessed-SubMental Fat Rating Scale (5-point scale, 0-No submental fat to 4-Excessive submental fat) at 4 weeks after the last treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Responder rate of 1-grade improvement in PA-SMFRS</measure>
    <time_frame>4 weeks after the last treatment session</time_frame>
    <description>Proportion of subjects who have at least a 1-grade improvement from basleine on the Patient Assessed-SubMental Fat Rating Scale (5-point scale, 0-No submental fat to 4-Excessive submental fat) at 4 weeks after the last treatment.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">168</enrollment>
  <condition>Submental Fat</condition>
  <arm_group>
    <arm_group_label>MT921</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1% or 1.5%, subcutaneously administered at most 50 injections per treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subcutaneously administered at most 50 injections per treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MT921</intervention_name>
    <description>Subcutaneously administered, 0.2ml per injection, at most 50 injections per treatment session.</description>
    <arm_group_label>MT921</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subcutaneously administered, 0.2ml per injection, at most 50 injections per treatment session.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects over 19 and under 65 years old

          -  Subjects achieving CA-SMFRS and PA-SMFRS score of 2 or 3

          -  Subjects who voluntarily signed the Informed Consent

        Exclusion Criteria:

          -  Subjects who had liposuction or other procedures on the treatment area that might
             affect the assessment.

          -  Subjects with BMI over 35.0kg/m^2

          -  Subjects with dysphagia

          -  Subjects who are allergic or hypersensitive to the investigational product

          -  Subjects who are pregnant or lactating, or does not agree to use an accepatble form of
             contraception during the clinical trial.

          -  Subjects who are otherwise deemed uneligible by the investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Se Min Park</last_name>
    <phone>02-6901-5859</phone>
    <email>seminp@medytox.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chung-ang University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>06973</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kim</last_name>
      <phone>02-1800-1114</phone>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 28, 2019</study_first_submitted>
  <study_first_submitted_qc>October 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 30, 2019</study_first_posted>
  <last_update_submitted>October 28, 2019</last_update_submitted>
  <last_update_submitted_qc>October 28, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

